The Rheumatology Advanced Practice Providers (RhAPP)

Welcome to the Content Rheum! RhAPP is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).

bshape_img

bgdots

bshape_img

section_img

Faculty

Lisa Asfahani

PA-C

Temecula, CA, USA

Monica Richey

NP

Great Neck, NY, USA

Candace Ryan

PA-C

Arizona Arthritis and Rheumatology Associates

Jeannette Hart

PA-C

Kadlec Clinic Rheumatology

Stacey Johnson

FNP-C

Montana Arthritis Center

Audrey Gibson

PA-C

Arthritis Center of North Georgia

Cassie Dolecki

PharmD

Autoimmunity Institute, Allegheny Health Network

Jennifer Mylod

DNP

Arizona Arthritis and Rheumatology Associates

William Saalfeld

NP

Arthritis Center of Nebraska

Wendy Simmons

PA-C

Carolina Arthritis Associates

Claudia Rivera Salas

NP

Lansing Rheumatology

Ingrid Pan

PharmD, BCPPS

University of Colorado

Christy Vath

PA-C

Seattle Rheumatology Associates Seattle, Washington

Jessica Farrell

PharmD

Albany Medical Center Division of Rheumatology Albany, New York

Heather Mambretti

PA-C

Texas Rheumatology

Robert Laugherty

JD, MBA, PA-C

East Tennessee Medical Group

Kyle George

PA-C

Boise, ID

Amanda Mixon

PA-C

UCHealth

Amber Hudgins

PharmD, SCP, CPP

Novant Health

Danielle Gatti-Palumbo

PharmD

Northwell Health Division of Rheumatology

Podcasts

RhAPPcast: Unmasking XLH: Misdiagnosed and Misunderstood

October 2025

RhAPPcast: Refractory PMR: When Steroids Aren’t Enough – Unmet Needs in Treatment

October 2025

RhAPPcast: The Safety Conversation: Upadacitinib in the Treatment of GCA

October 2025

RhAPPcast: Expanding the Arsenal: JAK Inhibitors in the Evolving GCA Landscape

September 2025

RhAPPcast: Inside the Evidence: A Deep Dive into the SELECT-GCA Study

September 2025

Laying the Foundation: Historical Approaches to GCA Treatment

September 2025

RhAPPcast: Spotting the Signs: Recognizing and Diagnosing Giant Cell Arteritis

August 2025

RhAPPcast: Foundations of PMR: Diagnosis, First-Line Therapy, and Tapering Strategies

August 2025

RhAPPcast: Understanding the TYK2/STAT Signaling Pathway in PsA: Clinical Implications and Beyond

July 2025

RhAPPcast: Practical Application: Integrating the New ACR LN Guidelines

May 2025

RhAPPcast: Decoding IL-17: Comparing and Contrasting IL-17A and IL-17F Inhibition

May 2025

RhAPPcast: The Relative Persistency and Effectiveness of Guselkumab in the Real-World

July 2025

RhAPPcast: Elevating Care in LN: What the New ACR Guidelines Mean for Patients & How APPs can Apply Them

July 2025

RhAPPcast: Navigating Leflunomide Use in Pregnant Patients with Sjögren’s Syndrome

March 2025

RhAPPcast: LN Updates Unpacked: Insights on New ACR Guidelines

February 2025

RhAPPcast: Navigating the Complexities: IL-17 Inhibitors and IBD Risk

November 2024

RhAPPcast: The Clinical Utility of Guselkumab in Axial PsA

January 2025

RhAPPcast: Lost Time: The Impact of Delaying Optimal Therapy in RA & SpA Patients Without Disease Control

October 2024

RhAPPcast: Navigating Remission in Rheumatoid Arthritis: Approaches, Advances, Impact, and Insights

October 2024

RhAPPcast: CD64+ Binding Description, Relevance, and Potential Clinical Implications

October 2024

RhAPP National 2025 Roundups

October 2025

RhAPP National 2025 Day 1 Roundup

October 2025

RhAPP National 2025 Day 2 RhAPPUp

October 2025

RhAPP National 2025 Day 3 Roundup

PMR

September 2025

Medication Review: What Is the Safety Profile of Sarilumab in PMR & RA?

August 2025

Comparative Effectiveness of Sarilumab vs. Methotrexate as a Corticosteroid-Sparing Agent in Patients with Polymyalgia Rheumatica

September 2025

Medication Review: How is Sarilumab Dosed & Administered for the Treatment of PMR & RA?

July 2025

Journal Club: Sarilumab for Relapse of Polymyalgia Rheumatica During Glucocorticoid Taper

September 2025

Medication Review: Key Patient Education When Starting Sarilumab for PMR or RA

October 2025

FAQ: What is the Inflation Reduction Act & How Does It Impact Affordability of Biologic Therapies?

September 2025

What is the Role of Sarilumab in Managing PMR?

August 2025

FAQ: Choosing Between Steroid-Sparing Agents in PMR Treatment

July 2025

FAQ: Steroid-Sparing Agent Consideration in PMR Management & What Options Are Available?

July 2025

What Are the Most Recent Treatment Guidelines for PMR, and What Are the Key Clinical Takeaways?

TYK2

June 2025

A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis

May 2025

What Is the Safety Profile of Deucravacitinib in PsO and PsA?

May 2025

What is the Mechanism of Action of Deucravacitinib?

May 2025

TYK2/STAT Pathway & Why TYK2 Therapy Works for Psoriasis and Psoriatic Arthritis

June 2025

How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles

Lupus Nephritis

May 2025

Voclosporin in Lupus Nephritis: New Insights on Efficacy & Safety from Clinical Trials

April 2025

Voclosporin for Lupus Nephritis: Efficacy & Safety Insights from AURORA 1 & 2 Trials

May 2025

What Are the Clinically Meaningful Differences Between Voclosporin and Other Calcineurin Inhibitors?

June 2025

According to the New 2024 ACR Guidelines for Lupus Nephritis, How Do You Monitor LN?

April 2025

What is the Safety Profile of Voclosporin and How Should it be Monitored?

April 2025

Voclosporin Dosing, Administration, Adjustments & Interactions

May 2025

Steroid Tapering in Lupus Nephritis: Insights from the 2024 ACR Guidelines

March 2025

What is Voclosporin and How Does it Work?

April 2025

What Are CNIs? Treating Lupus Nephritis with the Latest ACR Guidelines

March 2025

According to the New 2024 ACR Guidelines for LN, What Are the Treatment Goals For Patients With LN?

February 2025

According to the New 2024 ACR Guidelines, How Do You Treat LN?

February 2025

According to the new 2024 ACR Guidelines for Lupus Nephritis, How Should You Screen and Diagnose LN in Your SLE Patients?

February 2025

How is Lupus Nephritis Defined?

January 2025

How Long Has It Been Since the Last ACR LN Guideline Updates and Why Is This Significant?

csDMARDS

August 2025

Medication Review: Leflunomide Medication Review

July 2025

What is the Mechanism of Action of Methotrexate?

April 2025

Evaluating the Efficacy of Biologic With and Without Methotrexate

June 2025

Hydroxychloroquine Medication Review

January 2025

Effectiveness of Methotrexate and Leflunomide as Corticoid-Sparing Drugs

Biosimilars

October 2024

What Is the Difference Between Biosimilars and Generics?

September 2024

What Does It Mean for a Biosimilar to Be Interchangeable and Why Is That Important?

JAK

November 2024

Safety and Efficacy of Upadacitinib for Pediatric Patients with Polyarticular Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase-1 Trial

October 2024

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

October 2024

What Is the Safety Profile of Upadacitinib Across Indications?

September 2024

How Is Upadacitinib Dosed Across Rheumatologic Indications?

September 2024

Describe the Mechanism of Action of Upadacitinib

October 2024

Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies

October 2024

What Is the ORAL Surveillance Study and How Can It Be Applied to Clinical Practice?

October 2024

Variability in JAK Inhibition Specificity & Its Clinical Implications

September 2024

Provide Immunologic Rationale for JAK-Directed Therapy in Rheumatic Disease

September 2024

Describe JAK-STAT signaling in inflammation

IL-17

March 2025

Ixekizumab vs. Guselkumab in Plaque Psoriasis (12-Week Trial Results)

January 2025

Efficacy & Safety of Ixekizumab ± Methotrexate in PsA (52-Week SPIRIT-H2H)

June 2025

Can You Recapture Response to IL-17i Therapy After Interruption or Discontinuation in Therapy?

December 2024

What Is the Efficacy of Ixekizumab Across the GRAPPA and EULAR Domains?

April 2025

Are IL-17 Inhibitors Efficacious in Treating the Nail-DIP Complex in PsA?

October 2024

What Is the Safety Profile of Ixekizumab in PsA and axSpa?

February 2025

How Do You Explain The Timing of Ixekizumab's Clinical Efficacy to Patients?

September 2024

Describe The Mechanism of Action of Ixekizumab

September 2024

Provide Immunologic Rationale For IL17-Directed Therapy in PsA, AS, and nr-axSpA

August 2024

Describe the IL17-Induced Inflammatory Cascade

IL-23

October 2025

FAQ: What is the Effect of Guselkumab on Structural Damage in PsA?

March 2025

Long-Term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis)

May 2025

What is the Real World Evidence of Guselkumab in PsA

November 2024

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

April 2025

What is the Efficacy of Guselkumab Across the GRAPPA Domains?

September 2024

Data Review From the Phase III DISCOVER-2 Trials

July 2024

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

December 2024

What Is the Safety Profile of Guselkumab in PsO and PsA?

October 2024

How Is Guselkumab Dosed in PsO, PsA, and IBD?

March 2025

How do IL-23 and IL-17 Inhibitors Differ in Clinical Efficacy

February 2025

How Do You Interpret cDAPSA/DAPSA and MDA?

September 2024

Describe The Mechanism of Action of Guselkumab

August 2024

What is Non-Responder Imputation and How is it Utilized in Clinical Trials

February 2025

How Does Real-World Evidence Differ From Randomized Controlled Trials?

January 2025

How Do You Interpret Radiographic Progression Using Modified-vdHS or mTSS?

December 2024

How Does Axial PsA Differ From AS Clinically, Genetically, and Radiographically?

November 2024

Why is Binding CD64+ Important When Discussing IL23 Directed Therapy?

October 2024

Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.

September 2024

What is The Role of IL23/IL17 Axis in Rheumatic Disease

September 2024

Describe the IL23/IL17 Axis

May 2025

Define, Compare, and Contrast Humoral and Cell-Mediated Immunity

Publications

ECOSBot: a multicenter validation pilot study of a generative AI tool for OSCE-based nephrology training

October 2025

Case Report: Pemetrexed-induced pseudocellulitis: a rare adverse effect to be recognized for better management

October 2025

Topography of entheseal lesions on ultrasound: a comparative study between axial spondyloarthritis, psoriatic arthritis and healthy controls

October 2025

Practical survey on the use of herbal medicine by patients with systemic sclerosis

August 2025

Combination Therapy Using Embolization, Gelified Alcohol Sclerotherapy, and Vertebroplasty to Treat Aggressive Vertebral Hemangioma: Technique and Initial Results

June 2025

Percutaneous Pelvic Cementoplasty With or Without Screw Fixation in Patients Aged 70 Years and Over: Safety and Clinical Outcomes

June 2025

Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

May 2025

Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study

May 2025

The effectiveness of a 3-week spa therapy on the 6-month mobility and functional ability of patients with knee osteoarthritis: the ANGELLO randomized controlled trial

May 2025

From Risk Assessment to Management: Cardiovascular Complications in Pre- and Post-Kidney Transplant Recipients: A Narrative Review

April 2025

Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study

March 2025

Ureaplasma urealyticum septic hip arthritis associated with ocrelizumab therapy in a young patient with multiple sclerosis

January 2025

Comparison of Mesotherapy and Transcutaneous Electrical Nerve Stimulation (TENS) in the Management of Chronic Non-Specific Low Back Pain: A Randomized Clinical Trial

January 2025

Acute kidney injury as a key predictor of cardiovascular events in chronic kidney disease patients: the CKD-REIN study

December 2024

Enhancing vascular access planning in CKD: validating the 40% KFRE threshold for predicting ESKD in a French retrospective cohort study

October 2024

Mogamulizumab-induced bone granuloma

September 2024

Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype

September 2024

Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density

June 2024

Percutaneous Fixation with Internal Cemented Screws for Iliac Lytic Bone Metastases: Assessment of Pain and Quality of Life on Long Term Follow-up

May 2024

Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome

May 2024

section_img

dot_img

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play